美國電塔 AMT 深 滬
等待開盤 09-18 09:30:00 美东时间
176.55
+0.160
+0.09%
華盛通- 最 高176.895
- 今 開176.81
- 成交量 97.86万股
- 最 低 174.75
- 昨 收 176.39
- 總市值 822.65亿
- 52周最高 194.29
- 市盈率 靜 32.72
- 換手率 0.21%
- 52周最低 160.06
- 委 比 4.85%
- 總股本 4.66亿
- 歷史最高 271.85
- 量 比 0.90
- 振 幅 1.22%
- 歷史最低 -7.46
- 每 手 1
- 風險率 6.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多American Tower Completes $1.6 Billion Senior Notes Offering
An update from American Tower ( ($AMT) ) is now available. On September 14, 202...
09-15 05:54
J.P. Morgan downgrades Crown Castle to Sell equivalent
Crown Castle (CCI) was trading lower as J.P. Morgan cut its recommendation on the stock to Underweight from Neutral, and reduced the price target to $80.00 from $85.00. Shares were down 0.20% to $75.4...
09-14 19:53
American Tower prices $1.6B of senior notes
American Tower Corporation (AMT) announced on Wednesday the pricing of its registered public offering of senior unsecured notes due 2031, 2033, and 2036 in aggregate principal amounts of $500M, $500M...
09-10 05:40
内部人交易｜美国电塔披露一笔股票增持，金额约50.07万美元
美股上市公司美国电塔（AMT）披露一笔内部人股票交易。文件显示，公司内部人Kalathur (Rajesh)（Director）2026-08-21增持公司股票...
08-27 07:01
Welltower, Realty Income lead S&P Real Estate stocks on growth
As we navigate the third quarter of 2026, the S&P Real Estate sector continues to experience significant macroeconomic headwinds and shifting demand dynamics, making strategic stock selection and grow...
08-24 22:37
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Barclays Upgrades American Tower to Overweight, Raises Price Target to $198
Barclays analyst Brendan Lynch upgrades American Tower (NYSE:AMT) from Equal-Weight to Overweight and raises the price target from $195 to $198.
08-20 22:10
索罗斯长子Q2暴力买入存储芯片与AI算力！韩国股市ETF建仓即位列头号重仓，猛增台积电仓位
Soros Capital Management对于AI算力配置敞口全面加码，尤其对于台积电的持仓大幅增加逾1000%，至78,430股，价值约3746万美元。
08-19 11:45
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
